methyl (E)-3-(3-fluoro-4-(trifluoromethyl)phenyl)acrylate | 1007862-08-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: methyl (E)-3-(3-fluoro-4-(trifluoromethyl)phenyl)acrylate
• CAS: 1007862-08-9
• 化学式: C₁₁H₈F₄O₂
• 分子量: 248.177
• InChiKey: ILVBCOQGMQUIGK-HWKANZROSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.03
• 重原子数：
  17.0
• 可旋转键数：
  2.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  26.3
• 氢给体数：
  0.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  methyl (E)-3-(3-fluoro-4-(trifluoromethyl)phenyl)acrylate 在 palladium 10% on activated carbon 、 水 、 甲酸铵 、 三乙胺 、 三氟乙酸 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 lithium hydroxide 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 54.5h， 生成 (±)-(3S,4R)-N-{[4-(dimethylamino)phenyl]methyl}-4-[3-fluoro-4-(trifluoromethyl)phenyl]pyrrolidine-3-carboxamide
  参考文献：
  名称：

  4-芳基吡咯烷作为一类新型口服有效抗疟药。第 1 部分：4-芳基-N-苄基吡咯烷-3-甲酰胺的评价。

  摘要：

  鉴定具有抗疟功效的新型化学型对于对抗对当前抗疟药物产生耐药性的疟原虫物种的增加至关重要。我们使用混合靶标表型方法来识别和评估疟疾的新化学型。在我们在公开的表型抗疟数据库中寻找类似药物的天冬氨酸蛋白酶抑制剂时，我们发现了 GNF-Pf-4691，一种 4-芳基-N-苄基吡咯烷-3-甲酰胺，其结构让人想起已知的天冬氨酸蛋白酶抑制剂。对两个末端芳环的广泛分析揭示了结构-活性关系，其中在苄基位置上允许相对较少的取代基，但3-芳基位置允许一系列疏水基团和一些杂环。经过这项努力，我们确定 (+)-54b (CWHM-1008) 为先导化合物。54b对药物敏感的恶性疟原虫3D7和耐药的Dd2菌株的EC50值分别为46和21 nM。此外，54b 在小鼠中的半衰期较长（4.4 小时），并且口服对疟疾小鼠模型有效（每日一次；ED99 ∼ 30 mg/kg/天）。因此，4-芳基-N-苄基吡咯烷-3-甲酰胺化学型

  DOI：

  10.1021/acs.jmedchem.8b01972
• 作为产物：
  描述：

  3-氟-4-三氟甲基苯甲醛 、 三甲基膦酰基乙酸酯 在 sodium methylate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 methyl (E)-3-(3-fluoro-4-(trifluoromethyl)phenyl)acrylate
  参考文献：
  名称：

  Discovery of novel piperonyl derivatives as diapophytoene desaturase inhibitors for the treatment of methicillin-, vancomycin- and linezolid-resistant Staphylococcus aureus infections

  摘要：

  Inhibition of S. aureus diapophytoene desaturase (CrtN) could serve as an alternative approach for addressing the tricky antibiotic resistance by blocking the biosynthesis of carotenoid pigment which shields the bacterium from host oxidant killing. In this study, we designed and synthesized 44 derivatives with piperonyl scaffold targeting CrtN and the structure-activity relationships (SARs) were examined extensively to bring out the discovery of 21b with potent efficacy and better hERG safety profile compared to the first class CrtN inhibitor benzocycloalkane derivative 2. Except the excellent pigment inhibitory activity against wild-type S. aureus, 21b also showed excellent pigment inhibition against four pigmented MRSA strains. In addition, H2O2 killing and human whole blood killing assays proved 21b could sensitize S. aureus to be killed under oxidative stress conditions. Notably, the murine study in vivo validated the efficacy of 21b against pigmented S. aureus Newman, vancomycin-intermediate S. aureus Mu50 and linezolid-resistant S. aureus NRS271. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2017.12.090

文献信息

• Identification and characterization of pyrrolidine diastereoisomers as potent functional agonists and antagonists of the human melanocortin-4 receptor
  作者：Chen Chen、Wanlong Jiang、Joe A. Tran、Fabio C. Tucci、Beth A. Fleck、Stacy Markison、Jenny Wen、Ajay Madan、Sam R. Hoare、Alan C. Foster、Dragan Marinkovic、Caroline W. Chen、Melissa Arellano、John Saunders

  DOI：10.1016/j.bmcl.2007.10.115

  日期：2008.1

  A series of trans-4-phenylpyrrolidine-3-carboxamides were synthesized and characterized as potent ligands of the human melanocortin-4 receptor. Interestingly, a pair of diastereoisomers 13b displayed potent functional agonist and antagonist activity, respectively. Thus, the 3S,4R-pyrrolidine 13b-1 possessed a K-i of 1.0 nM and an EC50 of 3.8 nM while its 3R,4S-isomer 13b-2 exhibited a K-i of 4.7 and an IC50 of 64 nM. Both compounds were highly selective over other melanocortin receptor subtypes. The MC4R agonist 13b-1 also demonstrated efficacy in a diet-induced obesity model in rats. (C) 2007 Elsevier Ltd. All rights reserved.